{"id":1401,"date":"2015-10-28T11:42:15","date_gmt":"2015-10-28T10:42:15","guid":{"rendered":"https:\/\/blogdelarechercheclinique.com\/?p=1401"},"modified":"2025-05-21T11:10:15","modified_gmt":"2025-05-21T09:10:15","slug":"planete-oncologie-arc","status":"publish","type":"post","link":"https:\/\/blogdelarechercheclinique.com\/en\/planete-oncologie-arc\/","title":{"rendered":"Oncology Planet"},"content":{"rendered":"<h1>Oncology Planet<\/h1>\n<p>The CRA profession may be different according to the pathology on which you are required to work. Some diseases have specificities, especially if you have to work on an oncology study. Indeed, cancer follow up is long and specific and most of the time\u00a0files are heavy: there are more adverse events and concomitant medications. Furthermore, an oncology study involves a large number of on-site staff: nurses, pharmacists, radiologists, pathologists &#8230; Staff to be listed in the list of delegation of tasks and formed to the study. Moreover, these diseases have proper documents: did you know that the Oncological pharmacology society has released recommendations for the management of cytotoxic drugs? You will find them <a href=\"http:\/\/www.sfpo.com\/wp-content\/uploads\/2015\/05\/SFPO-Recommandations-EC-vfx3.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">here<\/a>.<\/p>\n<p>A brief overview of the oncology study specificities.<\/p>\n<div id=\"attachment_1404\" style=\"width: 310px\" class=\"wp-caption alignnone\"><a href=\"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920.jpg\"><img data-recalc-dims=\"1\" decoding=\"async\" aria-describedby=\"caption-attachment-1404\" class=\"size-medium wp-image-1404 lazyload\" data-src=\"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920-300x225.jpg?resize=300%2C225\" alt=\"Get you calculator and here we go !\" width=\"300\" height=\"225\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 300px; --smush-placeholder-aspect-ratio: 300\/225;\" \/><\/a><p id=\"caption-attachment-1404\" class=\"wp-caption-text\">Get your calculator and here we go !<\/p><\/div>\n<p><!--more--><\/p>\n<ol>\n<li>\n<h2><strong>The treatment response monitoring in oncology<\/strong><\/h2>\n<\/li>\n<\/ol>\n<p>Clinical trials in oncology is often judged in the patient\u00a0<a href=\"http:\/\/www.pneumocancero.com\/Livres\/Dictionnaire_methodologique\/survie_globale.html\" target=\"_blank\" rel=\"noopener noreferrer\">global survival<\/a> and \/ or the patient<a href=\"http:\/\/www.pneumocancero.com\/Livres\/Dictionnaire_methodologique\/survie_sans_aggravation.html\" target=\"_blank\" rel=\"noopener noreferrer\"> no relapse survival<\/a>. Patients will be followed for an indefinite period. A clinical trial in oncology can last several years.<\/p>\n<p>The investigating doctor will regularly evaluate the treatments response, data that you will have to monitor as a CRA. To assess the treatment response, the doctor has standardized scales, defined by the study protocol. Here are some example of scale:\u00a0<a href=\"http:\/\/www.cepd.fr\/CUSTOM\/RECIST_1.1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">RECIST<\/a>\u00a0(Response Evaluation Criteria In Solid Tumors) for solid tumors, the criteria of IMWG (International Myeloma Working Group) for myeloma or <a href=\"http:\/\/jco.ascopubs.org\/content\/25\/5\/579\/T2.expansion.html\" target=\"_blank\" rel=\"noopener noreferrer\">Cheson criteria<\/a> for lymphoma.<\/p>\n<p>These scales are composed of several parts:<\/p>\n<ul>\n<li>CR: Complete Response<\/li>\n<li>PR: Partial Response<\/li>\n<li>SD: Stable Disease<\/li>\n<li>PD: Progressive Disease<\/li>\n<\/ul>\n<p>Every\u00a0stage corresponds to a certain criteria such as the presence or the size of solid tumor (S), the plasma concentration of a protein&#8230;<\/p>\n<p>For this, you will use data called reference (baseline), collected before the treatment administration. For example, for the RECIST criteria, one or more target lesions will be selected. The treatment response will be checked against this reference value.<\/p>\n<p>However, if you notice the disease progression, it will be checked against the NADIR. The NADIR is the best response obtained since the treatment beginning. In the case of a solid tumor, NADIR will be the size of the smallest tumor observed since the beginning of the study.<\/p>\n<p>A tip, set up a table to document the different values measured at the baseline and during the study to evaluate the treatment response. So you will get all the values available for your calculations. Yes, you will weapon\u00a0yourself with your calculator to check disease progression \/ response and determine the response rate (in %).<\/p>\n<h2><strong>2. \u00a0Adverse events monitoring in Oncology<\/strong><\/h2>\n<p>As mentioned above, cancer is a serious illness and the treatments being cytotoxic, adverse events are more frequent. To evaluate them, the promoter will usually ask to rank them on a scale previously established: It will be asked to code the event on the CTCAE (Common Terminology Criteria for Adverse Events) established by the US oncology society, the NCI (National Cancer Institute) that you can find <a href=\"https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">here<\/a>.<\/p>\n<p><a href=\"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/CTCAE.png\"><img data-recalc-dims=\"1\" decoding=\"async\" class=\"size-medium wp-image-1402 aligncenter lazyload\" data-src=\"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/CTCAE-300x214.png?resize=300%2C214\" alt=\"CTCAE\" width=\"300\" height=\"214\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 300px; --smush-placeholder-aspect-ratio: 300\/214;\" \/><\/a><\/p>\n<p>For example, a hemoglobin rate at 9 g \/ dl is a grade II anemia according to CTCAE version 4.0. Be careful to the used version, it is specified in the protocol.<\/p>\n<p>This will allow you to check the gradation of the doctor. But beware; ask the doctor to indicate it in the patient&rsquo;s medical record because everything has to be documented in the patient&rsquo;s medical record: the adverse event, the start and end dates, grade, as well as the accountability to the treatment.<\/p>\n<h2><strong>3. Treatments accounting at the pharmacy<\/strong><\/h2>\n<p>Chemotherapy may be given in two forms: either as an injectable treatment, or as oral chemotherapy. In both cases, the CRA will check if the treatment\u00a0is\u00a0well followed, either by monitoring the chemotherapy preparation sheets, either by counting the tablets that the patient returned.<\/p>\n<p>Since the publication of the oncological pharmacology company\u00a0recommendations, some measures have been taken. Before, all the treatments were kept as well as their conditioning for the CRA to monitor accounting treatments. However, chemotherapy being cytotoxic treatments, security measures have been taken in some pharmacies. Indeed, according to recommendation n\u00b010 of the Oncological French Pharmacy Company, preparation for cancer treatment is followed by the immediate destruction of all container used for the said preparation. The pharmacy will not keep the treatments used in injectable form until your coming for monitoring. However, the center will provide you with a destruction process at the beginning of the study and a certificate of destruction after every\u00a0destruction. Secondary packaging if any (external cardboard box containing the product bottle) may however be preserved\u00a0for accounting. You will then use the treatments accounting paper, the preparation sheet and the external packaging for monitoring.<\/p>\n<p>In case of chemotherapy taken orally, the pharmacy realizes tablets accounting\u00a0the patient returned. As CRA, you would check if the accounting was correct. Recently, you&rsquo;re the one to check patient compliance in some pharmacies because according to recommendation n\u00b022 of the French Oncological Pharmacy Company, accounting of cytotoxic treatments is not carried out by the pharmacy staff for internal use. In all cases, make sure that your center keeps the bottles the patients returned.<\/p>\n<p>Finally, certain chemotherapies should be stored under certain\u00a0temperatures. Make sure to ask regularly to the pharmacist temperature readings to check\u00a0the products preservation. If treatments should be stored at an ambient temperature and that the site does not have an automatic temperature collection device, the center must use a thermometer indicating the minimum and maximum temperature reached. The center must raise that temperature indicating the minimum and maximum temperature reached; thus, temperature excursions can be identified. Some centers do not provide temperature readings, but provide a certificate of good conservation.<br \/>\nHere are some of the monitoring specificities in oncology. Obviously, there are other rating scales and tools used in the study protocols. Make sure to set up tools to monitor disease progression and time to review the patients medical records.<\/p>\n<p>Have you ever worked on cancer? What do you think of these features? Do you work with Pharmacies which already implemented the recommendations of the SFPO? How does it go daily and what do you think of these new measures<\/p>\n<p><strong><u>Sources<\/u><\/strong>:<\/p>\n<ul>\n<li><u><a href=\"http:\/\/www.sfpo.com\/wp-content\/uploads\/2015\/05\/SFPO-Recommandations-EC-vfx3.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Recommendations SFPO &#8211; Clinical Trials in Cancer May 2015<\/a><\/u><\/li>\n<li><u><a href=\"http:\/\/www.cepd.fr\/CUSTOM\/RECIST_1.1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">RECIST<\/a><\/u><\/li>\n<li><u style=\"line-height: 1.714285714; font-size: 1rem;\"><a href=\"http:\/\/www.sfrra.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Explanations of RECIST criteria<\/a><\/u><\/li>\n<li><u><a href=\"http:\/\/myeloma.org\" target=\"_blank\" rel=\"noopener noreferrer\">IMWG response criteria for myeloma<\/a><\/u><\/li>\n<li><u><a href=\"http:\/\/jco.ascopubs.org\/content\/25\/5\/579\/T2.expansion.html\" target=\"_blank\" rel=\"noopener noreferrer\">Cheson response criteria<\/a><\/u><\/li>\n<li><u><a href=\"https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">CTCAE<\/a><\/u><\/li>\n<\/ul>\n<p>If you liked this article, I invite you to click on \u00ab\u00a0I like\u00a0\u00bb or share with your CRA and project Manager colleagues and friends.<\/p>\n<p>Also, visit Pharmaspecific website : \u00a0<a href=\"http:\/\/www.pharmaspecific.fr\" target=\"_blank\" rel=\"noopener noreferrer\">http:\/\/www.pharmaspecific.fr<\/a>\u00a0and discover our activities.<\/p>\n<p>You can also visit the Facebook page of \u00ab\u00a0blog de la recherche clinique\u00a0\u00bb\u00a0and the\u00a0\u00ab\u00a0Pharmaspecific\u00a0\u00bb\u00a0and click on \u00ab\u00a0I like\u00a0\u00bb to support us.<\/p>\n<p>See\u00a0\u00ab\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/pharmaspecific\/\" target=\"_blank\" rel=\"noopener noreferrer\">Pharmaspecific Linkedin<\/a>\u00a0\u00bb\u00a0and\u00a0\u00ab\u00a0<a href=\"https:\/\/www.linkedin.com\/in\/vanessamontanari\/\" target=\"_blank\" rel=\"noopener noreferrer\">Vanessa Montanari Linkedin<\/a>\u00a0\u00bb\u00a0for more relevant news on clinical researches.<\/p>\n<p>See us as well on\u00a0<a href=\"http:\/\/fr.viadeo.com\/fr\/company\/pharmaspecific\" target=\"_blank\" rel=\"noopener noreferrer\">Pharmaspecific Viadeo<\/a>\u00a0and\u00a0<a href=\"https:\/\/viadeo.journaldunet.com\/p\/vanessa-montanari-820852\" target=\"_blank\" rel=\"noopener noreferrer\">Vanessa&rsquo;s Viadeo<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Article r\u00e9dig\u00e9 par la Soci\u00e9t\u00e9 Pharmaspecific, sp\u00e9cialiste en recherche clinique Plan\u00e8te oncologie Le m\u00e9tier d\u2019ARC peut \u00eatre diff\u00e9rent&#8230;<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"facebook_122143508198123560_331463380343150":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[450],"tags":[16,66,18,199,200],"class_list":{"0":"post-1401","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-actualites-de-la-recherche-clinique","7":"tag-arc","8":"tag-attache-de-recherche-clinique","9":"tag-investigateur","10":"tag-oncologie","11":"tag-pharmacie"},"translation":{"provider":"WPGlobus","version":"3.0.2","language":"en","enabled_languages":["fr","en"],"languages":{"fr":{"title":true,"content":true,"excerpt":false},"en":{"title":true,"content":true,"excerpt":false}}},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncology Planet -<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogdelarechercheclinique.com\/en\/planete-oncologie-arc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncology Planet -\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogdelarechercheclinique.com\/en\/planete-oncologie-arc\/\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/blogdelarechercheclinique\" \/>\n<meta property=\"article:published_time\" content=\"2015-10-28T10:42:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T09:10:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920-300x225.jpg\" \/>\n<meta name=\"author\" content=\"Vanessa Montanari\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Vanessa Montanari\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/\"},\"author\":{\"name\":\"Vanessa Montanari\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/13ee3f7a1251afe7e98918a482685938\"},\"headline\":\"Oncology Planet\",\"datePublished\":\"2015-10-28T10:42:15+00:00\",\"dateModified\":\"2025-05-21T09:10:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/\"},\"wordCount\":2661,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920-300x225.jpg\",\"keywords\":[\"ARC\",\"Attach\u00e9 de recherche clinique\",\"investigateur\",\"Oncologie\",\"Pharmacie\"],\"articleSection\":[\"Actualit\u00e9s de la recherche clinique\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/\",\"url\":\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/\",\"name\":\"Oncology Planet -\",\"isPartOf\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920-300x225.jpg\",\"datePublished\":\"2015-10-28T10:42:15+00:00\",\"dateModified\":\"2025-05-21T09:10:15+00:00\",\"description\":\"Certaines pathologies ont des sp\u00e9cificit\u00e9s, notamment si tu dois intervenir sur une \u00e9tude en oncologie. Le m\u00e9tier d'ARC peut donc \u00eatre tr\u00e8s diff\u00e9rent.\",\"breadcrumb\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#primaryimage\",\"url\":\"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920-300x225.jpg\",\"contentUrl\":\"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920-300x225.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/blogdelarechercheclinique.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Les sp\u00e9cificit\u00e9s du monitoring en oncologie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#website\",\"url\":\"https:\/\/blogdelarechercheclinique.com\/\",\"name\":\"Blog de la recherche clinique\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blogdelarechercheclinique.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#organization\",\"name\":\"Blog de la recherche clinique\",\"url\":\"https:\/\/blogdelarechercheclinique.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/04\/cropped-BLOG-logo.png?fit=512%2C512&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/04\/cropped-BLOG-logo.png?fit=512%2C512&ssl=1\",\"width\":512,\"height\":512,\"caption\":\"Blog de la recherche clinique\"},\"image\":{\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/blogdelarechercheclinique\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/13ee3f7a1251afe7e98918a482685938\",\"name\":\"Vanessa Montanari\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ddf428208f542d6c2239ace6606ebe9beb71049642a9c784967f23e4e76e8efc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ddf428208f542d6c2239ace6606ebe9beb71049642a9c784967f23e4e76e8efc?s=96&d=mm&r=g\",\"caption\":\"Vanessa Montanari\"},\"url\":\"https:\/\/blogdelarechercheclinique.com\/en\/author\/vanessa\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncology Planet -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogdelarechercheclinique.com\/en\/planete-oncologie-arc\/","og_locale":"en_US","og_type":"article","og_title":"Oncology Planet -","og_url":"https:\/\/blogdelarechercheclinique.com\/en\/planete-oncologie-arc\/","article_publisher":"https:\/\/www.facebook.com\/blogdelarechercheclinique","article_published_time":"2015-10-28T10:42:15+00:00","article_modified_time":"2025-05-21T09:10:15+00:00","og_image":[{"url":"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920-300x225.jpg","type":"","width":"","height":""}],"author":"Vanessa Montanari","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Vanessa Montanari","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#article","isPartOf":{"@id":"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/"},"author":{"name":"Vanessa Montanari","@id":"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/13ee3f7a1251afe7e98918a482685938"},"headline":"Oncology Planet","datePublished":"2015-10-28T10:42:15+00:00","dateModified":"2025-05-21T09:10:15+00:00","mainEntityOfPage":{"@id":"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/"},"wordCount":2661,"commentCount":0,"publisher":{"@id":"https:\/\/blogdelarechercheclinique.com\/#organization"},"image":{"@id":"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#primaryimage"},"thumbnailUrl":"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920-300x225.jpg","keywords":["ARC","Attach\u00e9 de recherche clinique","investigateur","Oncologie","Pharmacie"],"articleSection":["Actualit\u00e9s de la recherche clinique"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/","url":"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/","name":"Oncology Planet -","isPartOf":{"@id":"https:\/\/blogdelarechercheclinique.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#primaryimage"},"image":{"@id":"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#primaryimage"},"thumbnailUrl":"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920-300x225.jpg","datePublished":"2015-10-28T10:42:15+00:00","dateModified":"2025-05-21T09:10:15+00:00","description":"Certaines pathologies ont des sp\u00e9cificit\u00e9s, notamment si tu dois intervenir sur une \u00e9tude en oncologie. Le m\u00e9tier d'ARC peut donc \u00eatre tr\u00e8s diff\u00e9rent.","breadcrumb":{"@id":"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#primaryimage","url":"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920-300x225.jpg","contentUrl":"https:\/\/blogdelarechercheclinique.com\/wp-content\/uploads\/2015\/10\/business-861325_1920-300x225.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/blogdelarechercheclinique.com\/planete-oncologie-arc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/blogdelarechercheclinique.com\/"},{"@type":"ListItem","position":2,"name":"Les sp\u00e9cificit\u00e9s du monitoring en oncologie"}]},{"@type":"WebSite","@id":"https:\/\/blogdelarechercheclinique.com\/#website","url":"https:\/\/blogdelarechercheclinique.com\/","name":"Blog de la recherche clinique","description":"","publisher":{"@id":"https:\/\/blogdelarechercheclinique.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogdelarechercheclinique.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogdelarechercheclinique.com\/#organization","name":"Blog de la recherche clinique","url":"https:\/\/blogdelarechercheclinique.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogdelarechercheclinique.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/04\/cropped-BLOG-logo.png?fit=512%2C512&ssl=1","contentUrl":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/04\/cropped-BLOG-logo.png?fit=512%2C512&ssl=1","width":512,"height":512,"caption":"Blog de la recherche clinique"},"image":{"@id":"https:\/\/blogdelarechercheclinique.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/blogdelarechercheclinique"]},{"@type":"Person","@id":"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/13ee3f7a1251afe7e98918a482685938","name":"Vanessa Montanari","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogdelarechercheclinique.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ddf428208f542d6c2239ace6606ebe9beb71049642a9c784967f23e4e76e8efc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ddf428208f542d6c2239ace6606ebe9beb71049642a9c784967f23e4e76e8efc?s=96&d=mm&r=g","caption":"Vanessa Montanari"},"url":"https:\/\/blogdelarechercheclinique.com\/en\/author\/vanessa\/"}]}},"jetpack_featured_media_url":"","jetpack-related-posts":[{"id":14034,"url":"https:\/\/blogdelarechercheclinique.com\/en\/metier-arc-evolution-vanessa-montanari\/","url_meta":{"origin":1401,"position":0},"title":"Evoluer rapidement dans le m\u00e9tier d&rsquo;ARC","author":"Vanessa Montanari","date":"26 November 2014","format":false,"excerpt":"D\u00e9couvre comment faire une \u00e9volution rapide dans le m\u00e9tier d'ARC. Le t\u00e9moignage de Vanessa \u00e0 l'APEC.","rel":"","context":"In &quot;Strat\u00e9gie d'\u00e9volution pour atteindre vos objectifs&quot;","block_context":{"text":"Strat\u00e9gie d'\u00e9volution pour atteindre vos objectifs","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/strategie-devolution-pour-atteindre-vos-objectifs\/"},"img":{"alt_text":"\u00e9volution dans le m\u00e9tier d'ARC","src":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/evolution-arc.png?fit=851%2C565&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/evolution-arc.png?fit=851%2C565&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/evolution-arc.png?fit=851%2C565&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/evolution-arc.png?fit=851%2C565&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":489,"url":"https:\/\/blogdelarechercheclinique.com\/en\/metier-recherche-clinique\/","url_meta":{"origin":1401,"position":1},"title":"Faire conna\u00eetre le m\u00e9tier de la recherche clinique","author":"Vanessa Montanari","date":"27 November 2014","format":false,"excerpt":"D\u00e9couvre comment faire une \u00e9volution rapide dans le m\u00e9tier d'ARC. Si vous souhaitez des outils de travail, ou vous former, ou \u00eatre coacher, ou une r\u00e9ponse d'un juriste ou participer \u00e0 des webinaires au sujet de la recherche clinique, rendez-vous sur www.pharmaspecific-training.com","rel":"","context":"In &quot;Devenir Attach\u00e9 de recherche clinique: formation, financement&quot;","block_context":{"text":"Devenir Attach\u00e9 de recherche clinique: formation, financement","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/devenir-attache-de-recherche-clinique\/"},"img":{"alt_text":"Faire conna\u00eetre le m\u00e9tier d'attach\u00e9 de recherche clinique","src":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/03\/metier-dattache-de-recherche-clinique.png?fit=699%2C392&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/03\/metier-dattache-de-recherche-clinique.png?fit=699%2C392&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/03\/metier-dattache-de-recherche-clinique.png?fit=699%2C392&ssl=1&resize=525%2C300 1.5x"},"classes":[]},{"id":11936,"url":"https:\/\/blogdelarechercheclinique.com\/en\/attache-recherche-clinique-oncologie-clermont-ferrand\/","url_meta":{"origin":1401,"position":2},"title":"Attach\u00e9 de recherche clinique oncologie (H\/F) &#8211; Clermont-Ferrand","author":"Vanessa Montanari","date":"9 September 2022","format":false,"excerpt":"Vous aurez pour mission de suivre les \u00e9tudes cliniques. Garantir la qualit\u00e9 des donn\u00e9es recueillies et le respect de la r\u00e9glementation aupr\u00e8s des investigateurs.","rel":"","context":"In &quot;Pratiquer le m\u00e9tier d'Attach\u00e9 de recherche clinique&quot;","block_context":{"text":"Pratiquer le m\u00e9tier d'Attach\u00e9 de recherche clinique","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/pratiquer-le-metier-dattache-de-recherche-clinique\/"},"img":{"alt_text":"Recrutement Attach\u00e9 de Recherche Clinique","src":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2022\/09\/Recrutement-ARC.png?fit=1062%2C390&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2022\/09\/Recrutement-ARC.png?fit=1062%2C390&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2022\/09\/Recrutement-ARC.png?fit=1062%2C390&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2022\/09\/Recrutement-ARC.png?fit=1062%2C390&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2022\/09\/Recrutement-ARC.png?fit=1062%2C390&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":11932,"url":"https:\/\/blogdelarechercheclinique.com\/en\/technicien-etude-clinique-oncologie-bordeaux\/","url_meta":{"origin":1401,"position":3},"title":"Technicien d\u2019\u00e9tude clinique en Oncologie (H\/F) \u2013 Bordeaux","author":"Vanessa Montanari","date":"9 September 2022","format":false,"excerpt":"PR\u00c9SENTATION DE L\u2019ENTREPRISE Pharmaspecific est une entreprise \u00e0 taille humaine sp\u00e9cialis\u00e9e dans le conseil en recherche clinique. Notre structure assure le suivi d\u2019essais de m\u00e9dicaments pour le compte de laboratoires pharmaceutiques, de prestataires et aussi d\u2019organisations publiques ou priv\u00e9es en France ou \u00e0 l\u2019\u00e9tranger. Dans le cadre de notre d\u00e9veloppement,\u2026","rel":"","context":"In &quot;Pratiquer le m\u00e9tier d'Attach\u00e9 de recherche clinique&quot;","block_context":{"text":"Pratiquer le m\u00e9tier d'Attach\u00e9 de recherche clinique","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/pratiquer-le-metier-dattache-de-recherche-clinique\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":13972,"url":"https:\/\/blogdelarechercheclinique.com\/en\/les-groupes-cooperateurs-en-oncologie-gco-qui-sont-ils-2\/","url_meta":{"origin":1401,"position":4},"title":"Les Groupes Coop\u00e9rateurs en Oncologie (GCO): qui sont-ils?","author":"Vanessa Montanari","date":"8 July 2015","format":false,"excerpt":"Nous allons te dire dans cet article ce que nous avons retenu de cette entit\u00e9 pas toujours connue des attach\u00e9s de recherche clinique.","rel":"","context":"In &quot;Actualit\u00e9s de la recherche clinique&quot;","block_context":{"text":"Actualit\u00e9s de la recherche clinique","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/actualites-de-la-recherche-clinique\/"},"img":{"alt_text":"Les groupes coop\u00e9rateurs en oncologie","src":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/groupe-cooperateur-oncologie.png?fit=1027%2C687&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/groupe-cooperateur-oncologie.png?fit=1027%2C687&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/groupe-cooperateur-oncologie.png?fit=1027%2C687&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/05\/groupe-cooperateur-oncologie.png?fit=1027%2C687&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":14809,"url":"https:\/\/blogdelarechercheclinique.com\/en\/coordinateur-etudes-clinque-hopital\/","url_meta":{"origin":1401,"position":5},"title":"Coordinateur d&rsquo;\u00e9tudes cliniques \u00e0 l&rsquo;h\u00f4pital : Se former aux diff\u00e9rentes pathologies","author":"Vanessa Montanari","date":"9 July 2024","format":false,"excerpt":"Au cours de son cursus professionnel, le coordinateur d\u2019\u00e9tudes cliniques est amen\u00e9 \u00e0 travailler avec diff\u00e9rents promoteurs sur diff\u00e9rentes \u00e9tudes et sur de nombreuses pathologies.","rel":"","context":"In &quot;Strat\u00e9gie d'\u00e9volution pour atteindre vos objectifs&quot;","block_context":{"text":"Strat\u00e9gie d'\u00e9volution pour atteindre vos objectifs","link":"https:\/\/blogdelarechercheclinique.com\/en\/category\/strategie-devolution-pour-atteindre-vos-objectifs\/"},"img":{"alt_text":"Promoteur coordonnateur","src":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/07\/promoteur-coordonateur.png?fit=612%2C400&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/07\/promoteur-coordonateur.png?fit=612%2C400&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/blogdelarechercheclinique.com\/blog-contenu\/uploads\/2024\/07\/promoteur-coordonateur.png?fit=612%2C400&ssl=1&resize=525%2C300 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/posts\/1401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/comments?post=1401"}],"version-history":[{"count":1,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/posts\/1401\/revisions"}],"predecessor-version":[{"id":15335,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/posts\/1401\/revisions\/15335"}],"wp:attachment":[{"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/media?parent=1401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/categories?post=1401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogdelarechercheclinique.com\/en\/wp-json\/wp\/v2\/tags?post=1401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}